Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug
Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide. The post Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug appeared first on Investor's Business Daily.
Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.
The post Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
